drugset / Trial / NCT05655819

A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

NCT05655819

Phase 1/2 Completed 12 enrolled David J. Cangemi
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this research is to collect data from patients diagnosed with functional dyspepsia who are treated with glutamine and describe safety and treatment results compared to patients taking a placebo. Glutamine, an essential amino acid in humans, is an important energy source for cells lining the gastrointestinal tract and has been shown to play an important role in regulating the strength of the intestinal wall.

Timeline

Start
2023-02-16
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glutamine Other / unclassified 5 g Oral

Indications